Panion’s Q2-19 report, change of CFO, and end of contract for Business Development Director

The board of Panion Animal Health AB (“Panion”) adopted the Q2-19 report on the of August 2019.

At the same meeting, the board took decisions that reflects the strategy for Panion subsequent to CombiGene becoming the major shareholder and the change of members of Panion’s board;

  • Panion’s Business Development Director, Carlos N. Velez, was thanked for valuable work and input over the years and his contract will be terminated according to the agreement.
  • The CFO of Panion, Katarina Holm, Er Redovisning i Skåne AB, was thanked for excellent work in the time she served Panion and her contract will be terminated according to the agreement.
  • The board decided to appoint Anna Jönsson as new CFO for Panion. Anna Jönsson is already CFO in CombiGene AB, who is the major shareholder in Panion. Katarina Holm is available for Panion for a smooth transition.

Anja E. H. Holm, CEO
+ 45-22 94 66 00

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.